Targeting calcium/calmodulin-dependence kinase I and II as a potential anti-proliferation remedy for endometrial carcinomas

Cancer Letters

Volumn 277, Issue 2, 2009, Pages 235-243

  Takai, Noriyuki ^a   Ueda, Tami ^a   Nasu, Kaei ^a   Yamashita, Satoko ^a   Toyofuku, Mayo ^a   Narahara, Hisashi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Calcium; Calmodulin; Cell cycle; Endometrial cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE I; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; KN 92; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZYLAMINES; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 1; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CALMODULIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; SULFONAMIDES;

EID: 62749091611     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.12.018     Document Type: Article

References (35)

1. 2+/calmodulin-dependent protein kinase II is involved in hyperosmotic induction of the human taurine transporter. FEBS Lett. 569 (2004) 123-128
2. Rodriguez-Mora O., LaHair M., McCubrey J., and Franklin R. Calcium/calmodulin-dependent kinase I and calcium/calmodulin-dependent kinase participate in the control of cell cycle progression in MCF-7 human breast cancer cells. Cancer Res. 65 (2005) 5408-5416
3. 2+/calmodulin-dependent protein kinase kinase. J. Biol. Chem. 273 (1998) 21473-21481
4. 2+/calmodulin-dependent protein kinase IV. Identification of a brain CaM-kinase IV kinase. J. Biol. Chem. 269 (1994) 28640-28647
5. Racioppi L., and Means A.R. Calcium/calmodulin-dependent kinase IV in immune and inflammatory responses: novel routes for an ancient traveler. Trends Immunol. 29 (2008) 600-607
6. Howe C., LaHair M., Maxwell J., Lee J.T., Robinson P.J., Rodriguez-Mora O., McCubrey J.A., and Franklin R.A. Participation of the calcium/calmodulin-dependent kinases in hydrogen peroxide-induced Ikappa B phosphorylation in human T lymphocytes. J. Biol. Chem. 277 (2002) 30469-30476
7. Howe C., Lahair M., McCubrey J., and Franklin R. Redox regulation of the calcium/calmodulin-dependent protein kinases. J. Biol. Chem. 279 (2004) 44573-44581
8. Colbran R. Targeting of calcium/calmodulin-dependent protein kinase II. Biochem. J. 378 (2004) 1-16
9. 2+/calmodulin dependent protein kinase beta gene encodes multiple isoforms that display distinct kinase activity. J. Biol. Chem. 276 (2001) 31113-31123
10. Tombes R., and Krystal G. Identification of novel human tumor cell-specific CaMK-II variants. Biochim. Biophys. Acta. 1355 (1997) 281-292
11. Sherr C. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60 (2000) 3689-3695
12. Kahl C., and Means A. Regulation of cell cycle progression by calcium/calmodulin-dependent pathways. Endocr. Rev. 24 (2003) 719-736
13. 2+/CaM kinase). Cell Growth Differ. 6 (1995) 1063-1070
14. Kawamura K., Grabowski D., Krivacic K., Hidaka H., and Ganapathi R. Cellular events involved in the sensitization of etoposide-resistant cells by inhibitors of calcium-calmodulin-dependent processes. Role for effects on apoptosis, DNA cleavable complex, and phosphorylation. Biochem. Pharmacol. 52 (1996) 1903-1909
15. 2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. Biochem. Biophys. Res. Commun. 181 (1991) 968-975
16. Kahl C., and Means A. Regulation of cyclin D1/Cdk4 complexes by calcium/calmodulin-dependent protein kinase I. J. Biol. Chem. 279 (2004) 15411-15419
17. Shang S., Takai N., Nishida M., Miyazaki T., Nasu K., and Miyakawa I. CaMKIV expression is associated with clinical stage and PCNA-labeling index in endometrial carcinoma. Int. J. Mol. Med. 11 (2003) 181-186
18. Takai N., Miyazaki T., Fujisawa K., Nasu K., and Miyakawa I. Expression of c-Ets1 is associated with malignant potential in endometrial carcinoma. Cancer 89 (2000) 2059-2067
19. Takai N., Desmond J., Kumagai T., Gui D., Said J.W., Whittaker S., Miyakawa I., and Koeffler H.P. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin. Cancer Res. 10 (2004) 1141-1149
20. Takai N., Kawamata N., Gui D., Said J., Miyakawa I., and Koeffler H.P. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 101 (2004) 2760-2770
21. Rimon G., Bazenet C., Philpott K., and Rubin L. Increased surface phosphatidylserine is an early marker of neuronal apoptosis. J. Neurosci. Res. 48 (1997) 563-570
22. Chen Y., Kramer D., Diegelman P., Vujcic S., and Porter C. Apoptotic signaling in polyamine analogue-treated SK-MEL-28 human melanoma cells. Cancer Res. 61 (2001) 644-6437
23. Blagosklonny M., and Pardee A. The restriction point of the cell cycle. Cell Cycle 1 (2002) 103-110
24. Foster J., Henley D., Ahamed S., and Wimalasena J. Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol. Metab. 12 (2001) 320-327
25. Doisneau-Sixou S., Sergio C., Carroll J., Hui R., Musgrove E., and Sutherland R. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr. Relat. Cancer. 10 (2003) 179-186
26. Hickie R., Wei J., Blyth L., Wong D., and Klaassen D. Cations and calmodulin in normal and neoplastic cell growth regulation. Can. J. Biochem. Cell. Biol. 61 (1983) 934-941
27. Wei .J., Hickie R., and Klaassen D. Inhibition of human breast cancer colony formation by anticalmodulin agents: trifluoperazine, W-7, and W-13. Cancer Chemother. Pharmacol. 11 (1983) 86-90
28. Fu M., Wang C., Li Z., Sakamaki T., and Pestell R. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 145 (2004) 5439-5447
29. Sutherland R., and Musgrove E. Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res. 4 (2002) 14-17
30. 2+/calmodulin-dependent protein kinase II is required for microcystin-induced apoptosis. J. Biol. Chem. 277 (2002) 2804-2811
31. Xiao C., Yang B., Asadi N., Beguinot F., and Hao C. Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J. Biol. Chem. 277 (2002) 25020-25025
32. Wang C., Li N., Liu X., Zheng Y., and Cao X. A novel endogenous human CaMKII inhibitory protein suppresses tumor growth by inducing cell cycle arrest via p27 stabilization. J. Biol. Chem. 283 (2008) 11565-11574
33. Johnson D., and Walker C. Cyclins and cell cycle checkpoints. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 295-312
34. Sherr C. G1 phase progression: cycling on cue. Cell 79 (1994) 551-555
35. Kyushima N., Watanabe J., Hata H., Jobo T., Kameya T., and Kuramoto H. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables. J Cancer Res. Clin. Oncol. 128 (2002) 307-312